| 1 |
Chmiel P, Kłosińska M, Forma A, et al. Novel approaches in non-melanoma skin cancers-a focus on hedgehog pathway in basal cell carcinoma (BCC) [J]. Cells, 2022, 11(20): 3210.
|
| 2 |
Nasr I, McGrath EJ, Harwood CA, et al. British association of dermatologists guidelines for the management of adults with basal cell carcinoma 2021 [J]. Br J Dermatol, 2021, 185(5): 899-920.
|
| 3 |
国家皮肤与免疫疾病临床医学研究中心, 中国医师协会皮肤科分会. 中国皮肤基底细胞癌诊疗指南(2023版) [J].中华医学杂志, 2024, 104(6): 391-410.
|
| 4 |
Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial [J]. Lancet Oncol, 2021, 22(6): 848-857.
|
| 5 |
Cowey L, Chen CI, Aguilar KM, et al. Real-world treatment patterns and outcomes among patients with basal cell carcinoma following first-line hedgehog inhibitor discontinuation [J]. Dermatol Ther (Heidelb), 2022, 12(5): 1211-1224.
|
| 6 |
中华医学会皮肤性病学分会皮肤肿瘤研究中心, 中国医师协会皮肤科医师分会皮肤肿瘤学组.皮肤基底细胞癌诊疗专家共识(2021) [J]. 中华皮肤科杂志, 2021, 54(9): 757-764.
|
| 7 |
Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment [J]. Signal Transduct Target Ther, 2022, 7(1): 258.
|
| 8 |
Kong Y, Ma Y, Zhao X, et al. Optimizing the treatment schedule of radiotherapy combined with anti-PD-1/PD-L1 immunotherapy in metastatic cancers [J]. Front Oncol, 2021, 11: 638873.
|
| 9 |
Kong Y, Chen R, Xu M, et al. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study) [J]. BMJ Open, 2024, 14(3): e075642.
|
| 10 |
Kong Y, Zhao X, Xu M, et al. PD-1 inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase Ⅱ study [J]. Front Immunol, 2022, 13: 952066.
|
| 11 |
Kumar A, Taghi Khani A, Sanchez Ortiz A, et al. GM-CSF: a double-edged sword in cancer immunotherapy [J]. Front Immunol, 2022, 13: 901277.
|
| 12 |
Yu J, Yin L, Guo W, et al. Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase Ⅱ clinical trial [J]. Cancer Immunol Immunother, 2025, 74(3): 98.
|
| 13 |
Renga G, Bellet MM, Pariano M, et al. Thymosin α1 protects from CTLA-4 intestinal immunopathology [J]. Life Sci Alliance, 2020, 3(10): e202000662.
|
| 14 |
Du D, Song T, Dai H, et al. Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients [J]. Oncoimmunology, 2018, 7(8): e1450128.
|
| 15 |
徐美玲, 张辰阳, 邢鹏飞, 等.“布拉格治疗”PD-1及PD-L1抑制剂耐药的晚期难治性非小细胞肺癌1例 [J]. 中华医学杂志, 2023, 103(44): 3584-3586.
|
| 16 |
杨梦梦, 赵向荣, 陈光强, 等. 布拉格治疗联合维迪西妥单抗治疗HER2低表达的难治性乳腺癌1例 [J]. 中华转移性肿瘤杂志, 2024, 7(3): 252-255.
|
| 17 |
王娟, 陈大卫, 于金明. 放射远隔效应的量变到质变——布拉格治疗[J]. 中华肿瘤防治杂志, 2022, 29(18): 1314-1316.
|
| 18 |
周耀辉, 曾招林, 张祥银, 等. 基底细胞癌的靶向及免疫治疗研究进展 [J]. 皮肤病与性病, 2025, 47(2): 83-88.
|
| 19 |
赵雨晨, 李亚峰, 任海华, 等. 肿瘤微环境在基底细胞癌治疗中的研究进展 [J]. 中华整形外科杂志, 2023, 39(8): 921-926.
|